Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Executive Record

Francis deSouza

Chief executive: Illumina, Inc. (before 2014 to 11 Jun 2023)

28commitments announced
7with a clear outcome
5met on time
–rate shown after 15 outcomes

Commitments are credited to the chief executive in office on the day they were announced. Where a deadline fell after the leader left, the entry is marked. Sources for each leadership change: Illumina, Inc. filing.

Commitments announced under Francis deSouza

Illumina, Inc.announced 7 Feb 2023 Make Illumina Complete Long Read Prep with Enrichment available to customers due after leader left No record found31 Dec 2023
Illumina, Inc.announced 11 Jan 2023 Begin shipping the NovaSeq X series sequencer Met31 Mar 2023
Illumina, Inc.announced 11 Jan 2023 Ship 40 to 50 NovaSeq X instruments Met31 Mar 2023
Illumina, Inc.announced 11 Jan 2023 Ship over 300 NovaSeq X instruments during 2023 due after leader left Met31 Dec 2023
Illumina, Inc.announced 11 Jan 2023 Launch two Illumina complete long reads products due after leader left No record found31 Dec 2023
Illumina, Inc.announced 3 Nov 2022 Make the NovaSeq X Series (NovaSeq X and NovaSeq X Plus) available Met31 Mar 2023
Illumina, Inc.announced 3 Nov 2022 Make Illumina Complete Long-Reads available due after leader left No record found31 Dec 2023
Illumina, Inc.announced 3 Nov 2022 Make XLEAP-SBS Chemistry available on the NextSeq 1000/2000 due after leader left No record found31 Dec 2024
Illumina, Inc.announced 10 Feb 2022 Launch the Infinity long-read sequencing technology No record found31 Dec 2022
Illumina, Inc.announced 11 Jan 2022 Launch the NovaSeqDx sequencing system, including a version in China No record found31 Dec 2022
Illumina, Inc.announced 11 Jan 2022 Launch GRAIL's multi-cancer MRD test due after leader left No record found31 Dec 2023
Illumina, Inc.announced 11 Jan 2022 Launch TruSight NIPT as the first distributable IVD in the U.S. market due after leader left No record found31 Dec 2023
Illumina, Inc.announced 12 Jan 2021 Make Illumina Connected Analytics available to customers No record found31 Jan 2021
Illumina, Inc.announced 12 Jan 2021 Launch the new P1 NextSeq flow cell No record found31 Dec 2021
Illumina, Inc.announced 12 Jan 2021 Release new versions of Splice AI and Primate AI No record found31 Dec 2021
Illumina, Inc.announced 21 Sep 2020 Close the acquisition of GRAIL No record found31 Dec 2021
Illumina, Inc.announced 9 Jan 2019 Ship the S Prime flow cell for the NovaSeq platform No record found28 Feb 2019
Illumina, Inc.announced 9 Jan 2019 Ship the new 2x250 base pair iSeq flowcell kit No record found31 Mar 2019
Illumina, Inc.announced 9 Jan 2019 Deliver version 2 of the VeriSeq NIPT test No record found30 Jun 2019
Illumina, Inc.announced 5 Nov 2018 Close the acquisition of Pacific Biosciences by Illumina Withdrawn30 Jun 2019
Illumina, Inc.announced 11 Jan 2018 Submit VeriSeq NIPT regulatory applications in up to 12 additional countries No record found31 Dec 2018
Illumina, Inc.announced 11 Jan 2017 Launch VeriSeq NIPT in Europe Being checked31 Mar 2017
Illumina, Inc.announced 11 Jan 2017 File a Class 1 registration for solid tumor applications No record found30 Jun 2018
Illumina, Inc.announced 11 Jan 2017 Release the Firefly sequencer library prep box No record found31 Dec 2018
Illumina Inc.announced 2 Feb 2016 Make the Project Firefly NGS platform available No record found31 Dec 2017
Illumina Inc.announced 14 Jan 2016 Begin sequencing samples for the GRAIL venture Met31 Dec 2016
Illumina Inc.announced 14 Jan 2016 Initiate extensive clinical studies for the cancer screening test No record found31 Dec 2017
Illumina Inc.announced 14 Jan 2016 Launch a pan cancer asymptomatic screening test Not met31 Dec 2019

Is this record wrong, or are you Francis deSouza? Add a statement or ask for a correction.

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.